An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients

Trial Profile

An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Alipogene tiparvovec (Primary) ; Ciclosporin; Mycophenolate mofetil; Prednisolone
  • Indications Hyperlipoproteinaemia type I
  • Focus Therapeutic Use
  • Sponsors uniQure
  • Most Recent Events

    • 20 Jul 2017 Status changed from recruiting to withdrawn prior to enrolment because uniQure., has decided not to renew the Marketing Authorization of Glybera in the EU and this decision is not related to any safety, efficacy or quality issue .
    • 13 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 03 Oct 2016 Planned initiation date changed from 1 Sep 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top